Repligen jumps as bioprocessing recovery bid meets elevated short interest into earnings
Repligen shares rose Friday, April 17, 2026, as traders leaned into a bioprocessing recovery narrative following upbeat 2026 guidance and renewed bullish positioning. Elevated short interest heading into late April earnings is amplifying upside moves as the stock rebounds toward the mid-$130s.
1. What’s moving the stock today
Repligen (RGEN) is higher in Friday trading as investors continue to rotate into bioprocessing suppliers on expectations of improved demand and order normalization in 2026, with sentiment supported by the company’s most recent 2026 outlook. With short interest elevated into April, incremental buying pressure can translate into outsized daily gains as short sellers reduce exposure or get forced to cover on strength. (s205.q4cdn.com)
2. The fundamental backdrop: guidance reset higher
The latest company guidance calls for FY2026 revenue of $810 million to $840 million and adjusted diluted EPS of $1.93 to $2.01, a framework that has helped rebuild confidence after a volatile 2025 demand environment. Management has also been positioning the portfolio around newer modalities and analytics, including the acquired 908 Devices bioprocessing PAT assets, reinforcing the narrative that end-market recovery can translate into renewed growth. (s205.q4cdn.com)
3. Why the move can be sharp: short interest is high
Recent exchange data show Repligen’s short interest rose to about 5.56 million shares as of March 31, 2026 (roughly ~10% of shares outstanding/float depending on the dataset), setting up a market structure where positive momentum can mechanically accelerate if shorts de-risk. That positioning backdrop can matter especially as the market approaches the next earnings catalyst at the end of April. (chartexchange.com)
4. What to watch next
The next key catalyst is Repligen’s late-April earnings report (estimated for April 30, 2026), when investors will look for confirmation that demand is improving across chromatography, proteins, filtration, and analytics, and that 2026 margin targets remain intact. Any hint of delayed customer ordering, slower funnel conversion, or a weaker near-term revenue cadence could reverse the recent rebound, particularly after a multi-day run-up. (stockanalysis.com)